

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following groups of patients with hormone receptor (HR)-positive, HER2-negative breast cancer, 1 to 3 positive nodes and a 21-gene Recurrence Score® of 25 or lower derived a benefit in invasive disease-free survival (IDFS) with the addition of chemotherapy to adjuvant endocrine therapy in the RxPONDER trial?
  - a. Premenopausal women only
  - b. Postmenopausal women only
  - c. Both a and b
  - d. Neither a nor b
2. The EMBER-3 trial met its primary endpoint of improved progression-free survival with imlunestrant as monotherapy versus standard endocrine therapy for which population of patients with ER-positive, HER2-negative advanced breast cancer who had received prior endocrine therapy?
  - a. The overall patient population
  - b. The ESR1 mutation-positive population only
  - c. Both a and b
  - d. Neither a nor b
3. A 10-year update of the OlympiA trial of adjuvant olaparib for patients with germline BRCA1/2 mutation-positive, HER2-negative localized breast cancer demonstrated which of the following results?
  - a. Only the benefit in IDFS persists
  - b. Only the benefit in overall survival (OS) persists
  - c. Only the benefit in distant disease-free survival (DDFS) persists
  - d. The benefit in IDFS, OS and DDFS persists
4. What was the approximate reduction in the risk of disease progression or death with datopotamab deruxtecan compared to investigator's choice of chemotherapy for patients with previously treated HR-positive, HER2-negative breast cancer in the Phase III TROPION-Breast01 study?
  - a. 12%
  - b. 36%
  - c. 86%
5. Which of the following descriptions best reflects the mechanism of action of the novel agent sacituzumab tirumotecan?
  - a. HER2-directed antibody-drug conjugate (ADC)
  - b. TROP2-directed ADC
  - c. HER3-directed ADC